3rd Annual

Epigenetic Inhibitor Discovery

Targeting Histone Methyltransferases, Demethylases and Bromodomains

April 19-20, 2016

Epigenetic Inhibitor Discovery icon  

Targeting epigenetic modifiers and readers, particularly histone methyltransferases, demethylases and bromodomain-containing proteins have recently set the foundation for a new generation of anti-cancer drugs. Over the past few years, several companies have developed and successfully moved novel compounds targeting EZH2, DOT1L, LSD1, and a collection of BET bromodomain inhibitors into clinical studies. As these compounds continue to progress, developers are now focused on the discovery of new targets and designing novel inhibitors to expand into this robust target space. Of particular interest for discovery are non-BET bromodomain proteins and methyl lysine readers; arginine methyltransferases; and JmjC-domain containing demethylases. 

Cambridge Healthtech Institute will once again convene leaders in Epigenetic Inhibitor Discovery to bring forth novel and emerging strategies for inhibition, new bioactive tools and inhibitors, as well as strategies for lead optimization to obtain clinically relevant small molecules.

Topics may include, but are not limited to:

  • Coverage includes inhibitors targeting histone methyltransferases, demethylases and bromodomain-containing proteins
  • Discovery of inhibitors targeting non-BET bromodomain proteins, methyl lysine readers, arginine methyltransferases, lysine methytransferases (particularly G9a and SETD7), JmjC-domain containing demethylases
  • Case studies on the discovery and development of clinical-stage compounds
  • Structure and fragment-based design
  • Disrupting protein-protein interactions
  • Biochemical and biophysical assays
  • Chemical biology approaches 
  • Lead optimization

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 2, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5454
Email: kharry@healthtech.com

For partnering & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com